[144] Kura Oncology, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice summary: This filing reports a proposed sale of 4,541 shares of Kura Oncology common stock on NASDAQ through Morgan Stanley Smith Barney LLC on 09/29/2025. The shares were acquired as PSUs from the issuer on 09/27/2025. The filing lists an aggregate market value of $41,096.05 based on reported figures and shows 87,015,518 shares outstanding. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material information.

Insights

Financial Analyst

TL;DR: Routine insider notice for a small sale of recently vested PSUs; unlikely to be material to shareholders.

The filing documents a planned sale of 4,541 common shares with an aggregate market value of $41,096.05 executed via Morgan Stanley on 09/29/2025. The shares were acquired two days earlier as performance stock units (PSUs) from the issuer. No prior sales in the past three months are reported. Given the modest dollar value relative to the issuer's total outstanding shares, this transaction appears routine and not indicative of a significant change in insider exposure or company fundamentals.

Compliance/Risk Analyst

TL;DR: Filing meets Rule 144 disclosure elements and includes the required attestation; procedural compliance appears intact.

The notice contains required fields: broker name and address, number of shares, acquisition date, nature of acquisition (PSU), and planned sale date. The filer attests to lack of undisclosed material information and states there were no sales in the prior three months. From a compliance perspective, the form provides the necessary disclosure for a Rule 144 sale and does not raise immediate procedural concerns based on the provided data.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4541	41096.05	87015518	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/27/2025	PSU	Issuer			4541	09/29/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KURA Form 144 filed on 09/29/2025 report?

The form reports a proposed sale of 4,541 shares of Kura Oncology common stock through Morgan Stanley on 09/29/2025 with an aggregate market value of $41,096.05.

How were the shares in the KURA Form 144 acquired?

The shares were acquired as performance stock units (PSUs) from the issuer on 09/27/2025.

Does the KURA Form 144 show any other recent sales by the filer?

No. The filing states "Nothing to Report" under securities sold during the past three months.

Which broker is handling the proposed sale in the KURA Form 144?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY 10004.

How many shares outstanding does the Form 144 list for KURA?

The filing reports 87,015,518 shares outstanding for the issuer.